Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2014 Aug;23(8):1051-4. doi: 10.1517/13543784.2014.922953. Epub 2014 May 26.

Biomarkers and personalized therapy in chronic kidney diseases.

Author information

1
University of Bari and CARSO Consortium , Policlinico, Piazza G. Cesare 11, 70124 Bari , Italy +39 080 5478869 ; +39 080 5575710 ; paolo.schena@uniba.it.

Abstract

Numerous clinical trials are currently evaluating new strategies to halt the progression of renal damage in patients with chronic kidney diseases (CKDs). Unfortunately, none of them have considered that the lack of response to new therapies may be due to the pharmacogenetics/pharmacogenomics profile of the patient. The recent impact of high-throughput technologies used in genomics, proteomics and metabolomics may open a new way for discovering biomarkers that can provide us information about the mechanisms on the progression of renal damage. However, they can also be used for diagnosis and for selecting drugs, leading to personalized tailored therapy. The uses of classifiers formed by a list of genes, proteins and metabolites have been introduced into oncology and organ transplantation. These new approaches have recently also been used in the care of human glomerulonephritis. Integrating the large omic data sets with drug and disease databases could give the prediction of drug efficacy and side effects in CKDs.

KEYWORDS:

biomarkers; chronic kidney diseases; personalized therapy; pharmacogenetics; pharmacogenomics

PMID:
24857812
DOI:
10.1517/13543784.2014.922953
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center